HX116 / HanX Biopharma - LARVOL DELTA

A novel multi-modal PD-L1xVEGF-ADC, HX116, could be a new potent candidate treatment for pan-solid tumors (AACR 2026) - "As a result, HX116 showed poor cytotoxicity in these cells as compared to SGN-PDL1V, a PD-L1-MMAE-ADC that is internalized efficiently. The high safety and tolerability of HX116 will also be confirmed in NHP model. If all are confirmed, HX116 would become a powerful new candidate for future cancer treatment."

ADC • Oncology • Solid Tumor • PD-L1